Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?

Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?

Antiangiogenic therapy has shown promise in the treatment of patients with hepatocellular carcinoma (HCC). Bevacizumab, sorafenib, and sunitinib showed efficacy in patients with HCC; and sorafenib is approved by the FDA for treatment of this cancer. In practice, the clinical benefit of these agents...

Full description

Bibliographic Details
Main Authors: Justin B. Wenger, Napoleon Santos, Yanxia Liu, Jennifer Dallas, Sukanthini Subbiah, Steven Hochwald, Emina H. Huang, Long H. Dang, Carmen J. Allegra, Hendrik Luesch, Duyen T. Dang
Format: Article
Language:English
Published: Frontiers Media S.A. 2011-09-01
Series:Oncology Reviews
Subjects:
HIF-1a - HIF-2a - Antiangiogenic therapy - Hepatocellular carcinoma
Online Access:http://www.oncologyreviews.org/index.php/or/article/view/32

Internet

http://www.oncologyreviews.org/index.php/or/article/view/32

Similar Items